Should we tolerate tolerability as an objective in early drug development?

British Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2007, Pages 249-252

  Cohen, A ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; METHAMPHETAMINE; MORPHINE; NEOSTIGMINE; ROFECOXIB; TOLCAPONE; TUBOCURARINE CHLORIDE; XIMELAGATRAN;

ABDOMINAL PAIN; ADVERSE OUTCOME; ANALGESIC ACTIVITY; BLOOD PRESSURE MONITORING; DIAPHRAGM PARALYSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG INTOXICATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; EDITORIAL; FAINTNESS; FLUSHING; FOOD AND DRUG ADMINISTRATION; HUMAN; MUSCLE WEAKNESS; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; SOMNOLENCE; TOXICITY;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY, CLINICAL; PRACTICE GUIDELINES AS TOPIC;

EID: 34548038122     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03023.x     Document Type: Editorial

References (31)

1. Altman LK. The case of the queasy chemists. In : Who goes first. The story of self experimentation in medicine, 1st Edition, New York : Random House, 1987 : 86 105.
2. Goodyear M. Learning from the TGN1412 trial. BMJ 2006 332 : 677 78.
3. Kenter MJ, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 2006 368 : 1387 91.
4. Altman LK. The perilous route to painless surgery. In : Who goes first. The story of self experimentation in medicine, 1st Edition, New York : Random House, 1987 : 53 85.
5. FDA. Note for Guidance on General Considerations for Clinical Trials. Federal Register 62 (242). 17-12-1997.
6. Depre M, Ehrich E, Van Hecken A, De Lepeleire, Dallob A, Wong P, Porras A, Gertz BJ, De Shepper PJ. Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000 56 : 167 74.
7. Greenberg HE, Gottesdiener K, Huntington M, Wong P, Larson P, Wildonger L, Gillen L, Dorval E, Waldman SA. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol 2000 40 : 1509 15.
8. Jorga KM, Fotteler B, Heizmann P, Zurcher G. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 1998 54 : 443 47.
9. Watkins P. COMT inhibitors and liver toxicity. Neurology 2000 55 : S51 S52.
10. Bakri R, Wang J, Wierzbicki AS, Goldsmith D. Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. Int J Cardiol 2003 91 : 107 109.
11. Bischoff H, Heller AH. Preclinical and clinical pharmacology of cerivastatin. Am J Cardiol 1998 82 : 18J 25J.
12. Diener HC. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis 2006 21 : 279 93.
13. Wernevik LC, Nystrom P, Johnsson G, Nakanishi T, Eriksson UG. Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men. Clin Pharmacokinet 2006 45 : 77 84.
14. Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ 2003 327 : 1222 5.
15. Jewell RC, Khor SP, Kisor DF, LaCroix KA, Wargin WA. Pharmacokinetics of RheothRx injection in healthy male volunteers. J Pharm Sci 1997 86 : 808 12.
16. CORE trial group. Effects of RheothRx on mortality, morbidity, left ventricular function, and infarct size in patients with acute myocardial infarction. Collaborative Organization for RheothRx Evaluation (CORE). Circulation 1997 96 : 192 201.
17. Maynard C, Swenson R, Paris JA, Martin JS, Hallstrom AP, Cerqueira MD, Weaver WD. Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am Heart J 1998 135 : 797 804.
18. FDA Center for Drug evaluation and research. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Guidance for Industry. 1-7-2005.
19. TeGenero. TGN1412 Humanized agonistic anti CD28 monoclonal antibody, version 1.1 19-12-2005. 2005.
20. Parexel. Parexel Clinical Trial Protocol- A phase I single-centre, double blind, randomized, placebo-controlled, single escalating dose study to assess the safety, pharmacokinetics, pharmacodynamics and immunogenicity of TGN1412 administered intravenously to healthy volunteers. 21-12-2006. London.
21. MHRA. Pharmac-toxicological (Safety) assessment of TGN1412. EUDRACT2005-003371-21. 24-1-0006. London, MHRA.
22. Mayor S. Inquiry into adverse events in trial blames drug, not study design. BMJ 2006 332 : 870.
23. Warrington SJ. Limitations of dose tolerance studies on predictability for phase III. Arzneimittelforschung. 1985 35 : 781 3.
24. Boxenbaum H, DiLea C. First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 1995 35 : 957 66.
25. Forst T, Smith T, Schutte K, Marcus P, Pfutzner A. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain. Br J Clin Pharmacol 2007 63 : 75 82.
26. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007 64 : 292 303.
27. Civelli M, Preti AP, Cenacchi V, Cenacchi V, Rondelli I, Guastalla D, Tarral A, Dostert P, Guillevic, Homery MC. Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women. Br J Clin Pharmacol 2007 64 : 304 16.
28. Dingemanse J, van Gerven JM, Schoemaker RC, Roncari G, Oberye JJ, van Oostenbruggen MF, Massarella J, Segala P, Zell M, Cohen AF. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997 44 : 477 86.
29. van Gerven JM, Roncari G, Schoemaker RC, Massarella J, Keesmaat P, Kooyman H, Heizmann P, Zell M, Cohen AF, Dingemanse J. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997 44 : 487 93.
30. Leckridge R. Scottish GPs use of homeopathy. Br J Clin Pharmacol 2007 64 : 397.
31. Mathie RT, Fisher P. Homeopathy is safe and does not lack positive evidence in clinical trials. Br J Clin Pharmacol 2007 64 : 396.